Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry-Reference-Cited by-同舟云学术

Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

Published:2013-07-15 Issue:7 Volume:28 Page:907-914
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Carrascosa J.M.¹,Vilavella M.¹,Garcia-Doval I.²,Carretero G.³,Vanaclocha F.⁴,Daudén E.⁵,Gómez-García F.J.⁶,Herrera-Ceballos E.⁷,De la Cueva Dobao P.⁸,Belinchón I.⁹,Sánchez-Carazo J.L.¹⁰,Alsina M.¹¹,López-Estebaranz J.L.¹²,Ferrán M.¹³,Peral F.¹⁴,Torrado R.³,Rivera R.⁴,Jiménez-Puya R.⁶,Mendiola M.V.⁷,Ferrándiz C.¹,

Affiliation:

1. Hospital Universitari Germans Trías i Pujol, Badalona; Universitat Autònoma de Barcelona; Barcelona

2. Research Unit; Fundación Academia Española de Dermatología y Venereología [Spanish Academy of Dermatology and Venereology Foundation]; Madrid

3. Hospital Universitario de Gran Canaria Dr Negrín; Las Palmas de Gran Canaria

4. Hospital Universitario 12 de Octubre; Madrid

5. Hospital Universitario la Princesa; Madrid

6. Hospital Universitario Reina Sofía; Córdoba

7. Hospital Universitario Virgen de la Victoria; Málaga

8. Hospital Infanta Leonor; Madrid

9. Hospital General Universitario de Alicante; Alicante

10. Hospital General Universitario de Valencia; Valencia

11. Hospital Clinic de Barcelona; Barcelona

12. Hospital Universitario Fundación de Alcorcón; Madrid

13. Hospital del Mar; Parc de Salut Mar; Barcelona

14. Hospital Universitario Virgen de la Macarena; Sevilla Spain

Funder

Spanish Medicines and Health Products Agency (AEMPS)

Abbott

Pfizer

MSD

Janssen

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.12208/fullpdf

Reference24 articles.

1. Prevalence of psoriasis in Spain (Epiderma Project: phase I);Ferrándiz;J Eur Acad Dermatol Venereol,2001

2. International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review;Sterry;Br J Dermatol,2007

3. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study;Naldi;J Invest Dermatol,2005

4. WHO Physical status: the use and interpretation of anthropometry 1995 http://whqlibdoc.who.int/trs/WHO

5. The endocrine function of adipose tissue: an update;Ronti;Clin Endocrinol (Oxf),2006

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Etiopathogenesis of Psoriasis: Integration of Proposed Theories;Immunological Investigations;2024-01-19

2. Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR);Journal of Cutaneous Medicine and Surgery;2023-08-11

3. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS);British Journal of Dermatology;2023-07-21

4. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies;Dermatology and Therapy;2022-09-13

5. Successful use of anti‐IL ‐23 molecules in overweight‐to‐obese psoriatic patients: A multicentric retrospective study;Dermatologic Therapy;2022-09-09